ImmunoPrecise Antibodies
ImmunoPrecise Antibodies Ltd. is a biotherapeutic research and technology company specializing in the production of custom antibodies and related services. Headquartered in Fargo, North Dakota, the company operates in the United States, Canada, Europe, and internationally. Its extensive service offerings include B cell sorting, phage display production, transgenic animal models, and various antibody engineering techniques. The company has developed a reputation for its advanced capabilities in antibody discovery and development, leveraging systems biology, multi-omics modeling, and artificial intelligence to enhance efficiency and accuracy. ImmunoPrecise Antibodies engages in collaborations with academic and research institutions, including partnerships aimed at developing antibody-based tests for COVID-19 and neutralizing antibodies against SARS-CoV-2. Founded in 1989, the company continues to contribute to the advancement of novel biologics and therapeutic solutions for challenging diseases.
Top Sectors
Top Stages
4 past transactions
Carterra- LSA platform
Acquisition in 2024
Carterra- LSA platform is a versatile, fully integrated, high throughput monoclonal antibody (mAb) characterization platform that combines patented flow printing microfluidics with high throughput surface plasmon resonance (SPR) detection to deliver up to 100x the data in 10% of the time and with 1% of the sample requirements and consumable costs of other systems.
BioStrand
Acquisition in 2022
BioStrand, founded in 2019 and based in Diepenbeek, Belgium, specializes in advanced genomic variation identification technology. The company has developed a novel methodology that provides exceptional accuracy in identifying similarities and variations in genetic data, including DNA, RNA, and proteins. This innovative approach, which incorporates structural 3D information through its proprietary HYFTSTM technology, significantly enhances the analysis of genetic profiles. BioStrand's technology aims to drive advancements in precision medicine, drug development, and agriculture by facilitating improved understanding of diseases and biological processes.
ModiQuest B.V.
Acquisition in 2018
ModiQuest Research specializes in the generation of monoclonal antibodies targeting challenging antigens, catering to research and development, diagnostic, and therapeutic applications. The company employs proprietary technologies such as ModiFuse, ModiSelect, and ModiPhage to create extensive panels of monoclonal antibodies derived from various species, including mouse, rat, rabbit, chicken, llama, and human, as well as from transgenic animals with human immunoglobulin gene repertoires. In addition to lead antibody generation, ModiQuest offers a comprehensive suite of services that includes affinity maturation, humanization, stable cell line generation, and antibody production in both transient and stable mammalian systems. Through these capabilities, ModiQuest supports pharmaceutical and biotechnology companies in developing drugs for rare diseases, providing a broad range of technology and contract research solutions.
U-Protein Express
Acquisition in 2017
U-Protein Express B.V. is a contract research organization based in Utrecht, the Netherlands, specializing in the production and marketing of recombinant proteins and antibodies for research and pre-clinical applications. Founded in 2007, the company has successfully produced over 5,000 different recombinant antibodies and proteins, serving the biotech and pharmaceutical industries as well as academic institutions. U-Protein Express employs its proprietary rPEX technology, which boasts a success rate exceeding 90%, to facilitate the fast and large-scale production of challenging proteins, such as Fc-fusion proteins and bispecific antibodies. In addition to protein production, the company offers services in protein purification, recombinant antibody development, and monoclonal antibody generation, assisting clients in their research and development initiatives. U-Protein Express operates as a subsidiary of ImmunoPrecise Antibodies Ltd.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.